And...that’s a wrap for #ADPD2026!✨ What an unforgettable few days in Copenhagen - filled with inspiring science, meaningful connections, and incredible moments shared across the global AD/PD™ community. 🧠🌍 Thank you to everyone who joined us - onsite and online - for being part of this journey. 🇪🇸 We can’t wait to see you next year in Barcelona for AD/PD™ 2027! #Neuroscience #Alzheimers #Parkinsons #NeurodegenerativeDiseases #ADPDCommunity #SeeYouInBarcelona

📰 A New Crop of α-Synuclein Tracers Enter Human Testing “The field has made a lot of progress over the past year,” said Robert Mach of the University of Pennsylvania in Philadelphia. “We’re getting closer to having an α-synuclein radiotracer that could be used in large-scale clinical trials, though we’re not there yet,” he told Alzforum. Mach has spent more than a decade developing α-synuclein tracers. Gérard Bischof and Andrew Stephens of radiopharmaceuticals company Lantheus agreed. “Technological advances in the discovery of these compounds have led to the first set of candidates that may eventually be developed further”. 🔗 Continue reading: alzforum.org/news/conference…

Your research on β-Amyloid Diseases deserves a global stage! Abstract submissions for #ADPD2027 are officially open, and it’s time to share your latest findings, connect with the international neuroscience community, and help move the field forward! 🗓️ Deadline to submit: September 1, 2026 📬 Notification to accepted authors: October 2026 Explore more: adpd.kenes.com/abstract-topi… #ADPD #ADPD2027 #alzheimersresearch #dementiaresearch #neuroscience

Couldn't make it to Copenhagen or participate virtually? You can still register and watch all the content online! And if you were with us, you can rewatch anything you missed or revisit your favorite talks whenever you like. Just make sure you have the Gold Track upgrade - it gives you on-demand access to all sessions for six months after the Conference! 🧠 💻Start learning: bit.ly/3umKSQK 🖱️🔗Login: bit.ly/43K5ghm #ADPD2026

📰“It has become clear, thanks to the use of imaging and fluid-based biomarkers in conjunction with careful clinical phenotyping, that people have different trajectories once they start to accumulate amyloid.” - Henrik Zetterberg. At the annual #ADPD2027 conference, Gustav Ceder interviewed Henrik Zetterberg about what is top of mind in neurodegenerative disease research right now. Zetterberg splits his time between the University of Gothenburg, University of Wisconsin- Madison, and University College, London, and is a foremost expert on biomarkers in Alzheimer’s and related diseases. 🧠 In this Q&A, he explains why disease heterogeneity is emerging as a central theme in the field, how broad biomarker panels can drive discovery, and which molecular patterns and biomarker advances he believes are most likely to matter in research and clinical practice. 🔬 🥼 🔗Continue reading: alzforum.org/news/conference…

The next breakthrough starts with your abstract! Submissions for #ADPD2027 are now open - join thousands of researchers and clinicians advancing the future of neurodegenerative disease research. 📅 Submit by September 1, 2026 📢 Acceptance notifications in October 2026 Take the next step and submit your research 👇 adpd.kenes.com/abstract-subm… #alzheimersresearch #parkinsonsresearch #neuroscience

AD/PD™ 2026 brought together: ✔️ 5900 delegates ✔️ 2700 abstracts ✔️ 734 talks Turn the latest Alzheimer’s disease research into practical clinical insights with the on-demand AD/PD™ 2026 Evidence to Asian Practice: AD Session. Gain expert perspectives on emerging therapies, biomarkers, early diagnosis, and regionally relevant approaches to improving patient care across Asia. 📽️ LEARN MORE & WATCH NOW: bit.ly/49qVpjU #ADPD2026 #ADPDonUNLOK #ADPDEducation #Alzheimers #Parkinsons

Get ready for AD/PD™ 2027!🙋✨🌴 The 21st edition of the groundbreaking series of Alzheimer's and Parkinson's disease and related disorders conferences will take place in the captivating city of Barcelona, Spain, on 🗓️ March 16-20, 2027. 👋 🇪🇸 We invite you to join the AD/PD™ community, among which we are proud to count the field's leading international scientists, clinicians, and innovators! Registration and abstract submission will open soon! Stay tuned and be the first to secure your spot in Barcelona!🔗Find out more: adpd.kenes.com/ #ADPD2027 #Alzheimers #Parkinsons

🧠 BEST OF AD/PD™ 2026: China Session Join international experts for an insightful session focused on the early identification of Alzheimer’s disease through novel biomarkers and cognitive assessment strategies. 📅 Sunday, 17th May 2026 ⏰ 08:30-09:45 (China Standard Time) No pre-registration is needed. Click here to join the live session on 17th May: bit.ly/4tAy8TQ 👈 🎙️Guest Speakers: Prof. Weishi Wei, Prof. Samuel N. Lockhart, Prof. Michelle M. Mielke and Prof. Sid O’ Bryant Session highlights include: ✔️ Blood biomarkers and cognitive assessment in primary care pathways ✔️ Advances in cognitive testing implementation ✔️ Precision medicine approaches across diverse populations ✔️ Insights from the HABS-HD study ✔️ Expert panel discussion Do not miss this expert-led session. Join global experts and elevate your clinical approach. #ADPD #ADPD2026 #ADPDonUNLOK #ADPDEducation #AlzheimersDisease #Neurology #Biomarkers #PrecisionMedicine #MedicalEducation #UNLOKEducation

🤓 Translate the latest Alzheimer’s disease research into real-world clinical practice with the on-demand AD/PD™ 2026 Evidence to Asian Practice: AD Session. Explore expert insights on emerging therapies, biomarkers, early diagnosis, and regionally relevant strategies for improving patient care across Asia. 📽️ LEARN MORE & WATCH NOW: bit.ly/49qVpjU #ADPD2026 #ADPDonUNLOK #ADPDEducation #Alzheimer #Parkinson

📰Does α-Synuclein Immunotherapy Slow Parkinson’s, After All? "Can targeting α-synuclein slow the course of Parkinson’s disease? Despite years of trying, success has eluded scientists thus far. At the AD/PD conference, held March 17-21 in Copenhagen, Denmark, Roche scientists finally offered some evidence for this, citing 2.5 years of long-term extension data from the Phase 2b Padova trial of their anti-α-synuclein antibody prasinezumab.🔬 🔗" Continue reading: alzforum.org/news/conference…

🎉 We have our winners! 🎉 A huge shoutout to the champions of the UNLOK in 4 Steps Challenge: ✨ Dr. Neelam Younas Postdoctoral Researcher, University of Medicine Göttingen, Germany ✨ Dr. Gerardo Ongari Postdoctoral Researcher, Uppsala University, Sweden We can’t wait to welcome you both to Barcelona for AD/PD™ 2027, see you there! 🇪🇸 To everyone who took part - thank you for your enthusiasm and contributions. You’re what keeps this community thriving and growing every day. 💙 #ADPDonUNLOK #ADPDEducation #UNLOKEducation #ADPD2026 #ADPD2027

📰 The Big Picture: Three Inflection Points Mark the Amyloid Cascade "During five 11-hour days in Copenhagen, Denmark, nearly 6,000 attendees soaked up talks and posters at the 20th International Conference on Alzheimer’s and Parkinson’s Diseases. From March 17-21, speakers discussed the latest on biomarkers, immunotherapy, neuroinflammation, vascular contributions to dementia, drug trials, and more. Artificial intelligence was everywhere, with talks speckled throughout the program and the AD Data Initiative awarding two Alzheimer’s Insights AI Prizes at week’s end."🧠🔗Continue reading: alzforum.org/news/conference…

Digital biomarkers and artificial intelligence could revolutionize dementia research and clinical practice - but how can they be integrated into workflows? Prof. Rhoda Au of @BUMedicine shares insights in this interview👇 ow.ly/iKZe50YB6XS #ADPD2026 @adpdnet #AlzheimersDisease #NeuroTwitter

🧠🗣️It was a pleasure to speak at the AD/PD conference in Copenhagen, Denmark. Without broader biomarkers across populations, precision medicine cannot truly become precise. @adpdnet @UNTHealthITR #ADPD2026 #Neuroscience #Research #Biomarkers #Brainhealth4all

📰At C-BRAIN Workshop, Scientists Test-Drive New AI Agents "At last year’s AD/PD meeting in Vienna, what is now the Consortium for Biomedical Research and AI in Neurodegeneration was an idea. By this year’s AD/PD in Copenhagen, C-BRAIN had become an operating consortium with a $10M budget that offered up its first prototype AI tools for scientists to try out and critique. The best of these will be combined toward C-BRAIN’s ultimate goal of building an “AI co-scientist” that aids Alzheimer’s researchers in their quest to make discoveries that lead to better therapies."🔗👉Continue reading: alzforum.org/news/conference… #ADPD2026

🏆 And the winner is… Congratulations to Rodrigo for winning the #ADPD2026 Photo Contest! 📸✨ His posts truly captured the spirit, energy, and community of AD/PD™ in Copenhagen. Thank you to everyone who participated and shared their amazing moments with us. 💙 #Neuroscience #Alzheimers #Parkinsons #SeeYouInBarcelona

📰AI, Biomarkers and Biological Insights Converge at #ADPD2026 "Meetings like this highlight how much progress is being driven by open data, global collaboration, and stronger connections between Alzheimer’s and Parkinson’s researchers,” said Mark Frasier, PhD, a chief scientist at @MichaelJFoxOrg. “By sharing insights across diseases and disciplines, scientists can uncover common mechanisms and accelerate discovery in ways that simply weren’t possible before."🔗👉Continue reading: michaeljfox.org/news/ai-biom…

🧠 AD/PD 2026 highlights: Advancing early detection, diagnostics and therapeutics across neurodegenerative diseases Insights from the Alzheimer’s and Parkinson’s Diseases Conference 2026 highlighted continued progress in early detection, precision diagnostics and emerging therapies across neurodegenerative diseases. Key themes included: • Earlier detection using biomarkers and real-world data • Integration of artificial intelligence in clinical practice • Novel therapies targeting underlying disease biology 🔗 Read more: touchneurology.com/insight/a… @adpdnet #ADPD2026 #Neurology #NeurodegenerativeDiseases #PrecisionMedicine

Massive thanks to Dr Sid O'Bryant (@TheBrainCareDoc) for discussing the importance of representing diverse populations in AD research with us at #ADPD2026. 👉ow.ly/Q7sU50YyfY2 #Dementia #Neurology #ADPD2026 @adpdnet